Merdury Biopharmaceutical (6932.TWO) Stock Price

Merdury Biopharmaceutical Price

CLOSED
5.25TWD+0.12 (+2.31 %)
Market closed

Revenue has compounded at 36.1% per year over the past 2 years to 4.96 M TWD. Merdury Biopharmaceutical's net margin stands at -1,018.9%, up from -1,166.0% several years earlier. The stock trades about 5% above its 52-week low.

Merdury Biopharmaceutical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Merdury Biopharmaceutical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Merdury Biopharmaceutical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Merdury Biopharmaceutical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Merdury Biopharmaceutical Stock Price History
DateMerdury Biopharmaceutical Price
8/10/20265.25 TWD
8/7/20265.13 TWD
8/6/20265.11 TWD
8/5/20265.06 TWD
8/4/20265.03 TWD
8/3/20264.98 TWD
7/31/20264.98 TWD
7/30/20265.00 TWD
7/29/20265.34 TWD
7/28/20265.42 TWD
7/27/20265.67 TWD
7/24/20265.67 TWD
7/23/20265.67 TWD
7/22/20265.68 TWD
7/21/20265.69 TWD
7/20/20265.54 TWD
7/17/20265.83 TWD
7/16/20265.89 TWD
7/15/20265.94 TWD
7/14/20265.93 TWD
7/13/20266.00 TWD
7/10/20266.08 TWD
7/9/20266.08 TWD
7/8/20265.95 TWD
7/7/20266.09 TWD
7/6/20266.08 TWD
7/3/20266.09 TWD
7/2/20266.08 TWD
7/1/20266.09 TWD
6/30/20266.04 TWD
6/29/20266.20 TWD
6/26/20266.29 TWD
6/25/20266.67 TWD
6/24/20266.71 TWD
6/23/20266.73 TWD
6/22/20266.30 TWD
6/18/20266.49 TWD
6/17/20266.39 TWD
6/16/20266.59 TWD
6/15/20266.69 TWD
6/12/20266.57 TWD
6/11/20266.57 TWD
6/10/20266.74 TWD
6/9/20266.79 TWD
6/8/20266.88 TWD
6/5/20266.99 TWD
6/4/20266.72 TWD
6/3/20266.60 TWD
6/2/20266.70 TWD
6/1/20266.91 TWD
5/29/20267.00 TWD
5/28/20266.89 TWD
5/27/20266.72 TWD
5/26/20266.86 TWD
5/25/20266.83 TWD
5/22/20267.05 TWD
5/21/20266.99 TWD
5/20/20267.03 TWD
5/19/20267.14 TWD
5/18/20267.19 TWD
5/15/20267.00 TWD
5/14/20267.19 TWD
5/12/20267.79 TWD
5/8/20267.98 TWD
5/7/20267.99 TWD
5/6/20267.80 TWD
5/5/20268.18 TWD
5/4/20268.22 TWD
4/30/20268.26 TWD
4/29/20268.31 TWD
4/28/20268.27 TWD
4/27/20268.35 TWD
4/24/20268.29 TWD
4/23/20268.11 TWD
4/22/20268.24 TWD
4/21/20268.05 TWD
4/20/20268.08 TWD
4/17/20268.19 TWD
4/16/20268.05 TWD
4/15/20267.01 TWD
4/14/20267.24 TWD
4/13/20267.24 TWD
4/10/20267.38 TWD
4/9/20267.56 TWD
4/8/20267.63 TWD
4/7/20267.99 TWD
4/2/20267.84 TWD
4/1/20267.80 TWD
3/31/20267.64 TWD
3/30/20267.79 TWD
3/27/20267.99 TWD
3/26/20268.02 TWD
3/25/20268.00 TWD
3/24/20267.89 TWD
3/23/20267.92 TWD
3/20/20267.71 TWD
3/19/20268.09 TWD
3/18/20268.01 TWD
3/17/20268.05 TWD
3/16/20268.06 TWD
3/13/20268.24 TWD
3/12/20268.16 TWD
3/11/20268.66 TWD
3/10/20268.60 TWD
3/9/20267.99 TWD
3/6/20268.29 TWD
3/5/20267.96 TWD
3/4/20267.80 TWD
3/3/20268.45 TWD
3/2/20268.61 TWD
2/26/20268.75 TWD
2/25/20268.92 TWD
2/24/20268.80 TWD
2/23/20268.59 TWD
2/11/20268.55 TWD
2/10/20268.80 TWD
2/9/20268.86 TWD
2/6/20268.79 TWD
2/5/20268.60 TWD
2/4/20268.55 TWD
2/3/20268.37 TWD
2/2/20268.82 TWD
1/30/20269.04 TWD
1/29/20269.13 TWD
1/28/20269.01 TWD
1/27/20269.30 TWD
1/26/202610.10 TWD
1/23/202610.25 TWD
1/22/20269.14 TWD
1/21/20269.04 TWD
1/20/20269.98 TWD
1/19/20269.45 TWD
1/16/20269.04 TWD
1/15/20268.79 TWD
1/14/20269.02 TWD
1/13/20267.98 TWD
1/12/20268.03 TWD
1/9/20268.03 TWD
1/8/20268.02 TWD
1/7/20268.01 TWD
1/6/20268.11 TWD
1/5/20268.42 TWD
1/2/20268.51 TWD
12/31/20258.32 TWD
12/30/20258.15 TWD
12/29/20258.15 TWD
12/26/20258.42 TWD
12/24/20258.49 TWD
12/23/20258.35 TWD
12/22/20258.56 TWD
12/19/20258.75 TWD
12/18/20258.88 TWD
12/17/20259.10 TWD
12/16/20258.65 TWD
12/15/20257.96 TWD
12/12/20258.54 TWD
12/11/20259.12 TWD
12/10/20259.46 TWD
12/9/20259.65 TWD
12/8/202510.70 TWD
12/5/202511.15 TWD
12/4/202510.75 TWD
12/3/202511.10 TWD
12/2/202511.25 TWD
12/1/202511.45 TWD
11/28/20259.99 TWD
11/27/20259.80 TWD
11/26/20259.75 TWD
11/25/20259.87 TWD
11/24/20259.74 TWD
11/21/20259.77 TWD
11/20/20259.82 TWD
11/19/20259.70 TWD
11/18/20259.48 TWD
11/17/202510.10 TWD
11/14/202510.10 TWD
11/13/202510.15 TWD
11/12/202510.20 TWD
11/11/20259.18 TWD
11/10/20258.95 TWD
11/7/20259.51 TWD
11/6/20259.98 TWD
11/5/20258.58 TWD
11/4/20257.36 TWD
11/3/20257.03 TWD
10/31/20257.05 TWD
10/30/20256.67 TWD
10/29/20255.89 TWD
10/28/20255.67 TWD
10/27/20255.48 TWD
10/23/20255.56 TWD
10/22/20255.64 TWD
10/21/20255.67 TWD
10/20/20255.60 TWD
10/17/20255.60 TWD
10/16/20255.67 TWD
10/15/20255.52 TWD
10/14/20255.60 TWD
10/13/20255.40 TWD
10/9/20255.60 TWD
10/8/20255.70 TWD
10/7/20255.85 TWD
10/3/20255.33 TWD
10/2/20255.04 TWD
10/1/20255.02 TWD
9/30/20255.04 TWD
9/26/20255.48 TWD
9/25/20255.51 TWD
9/24/20255.49 TWD
9/23/20255.39 TWD
9/22/20256.00 TWD
9/19/20256.17 TWD
9/18/20256.21 TWD
9/17/20256.50 TWD
9/16/20256.26 TWD
9/15/20256.27 TWD
9/12/20256.93 TWD
9/11/20257.22 TWD
9/10/20257.50 TWD
9/9/20257.09 TWD
9/8/20257.75 TWD
9/5/20258.00 TWD
9/4/20258.01 TWD
9/3/20258.17 TWD
9/2/20258.12 TWD
9/1/20258.08 TWD
8/29/20258.30 TWD
8/28/20258.53 TWD
8/27/20258.54 TWD
8/26/20258.67 TWD
8/25/20258.50 TWD
8/22/20258.70 TWD
8/21/20258.70 TWD
8/20/20258.91 TWD
8/19/20258.80 TWD
8/18/20258.81 TWD
8/15/20258.83 TWD
8/14/20258.91 TWD
8/13/20258.83 TWD
Access this data via the Eulerpool API
Get Free API Key

Merdury Biopharmaceutical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 TWD
-199,000.00 TWD
-199,000.00 TWD
Jan 1, 2020
0.00 TWD
-210,000.00 TWD
-210,000.00 TWD
Jan 1, 2021
0.00 TWD
-5.30 M TWD
-5.31 M TWD
Jan 1, 2022
2.68 M TWD
-31.18 M TWD
-31.25 M TWD
Jan 1, 2023
1.03 M TWD
-43.11 M TWD
-43.82 M TWD
Jan 1, 2024
4.96 M TWD
-54.04 M TWD
-50.57 M TWD
Jan 1, 2025
0.00 TWD
-68.55 M TWD
-67.23 M TWD

Merdury Biopharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 10:33 AM
 
REVENUEM TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM TWD
EBITM TWD
EBIT MARGIN%
NET INCOMEM TWD
NET INCOME GROWTH%
SHARESM
2019202020212022202320242025
–––2.001.004.00–
––––-50.00300.00–
–––50.00400.00100.00–
4.004.004.001.004.004.004.00
––-5.00-31.00-43.00-54.00-68.00
–––-1,550.00-4,300.00-1,350.00–
––-5.00-31.00-43.00-50.00-67.00
–––520.0038.7116.2834.00
406.48413.50413.50401.50416.06457.55413.50
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Merdury Biopharmaceutical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Merdury Biopharmaceutical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Merdury Biopharmaceutical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Merdury Biopharmaceutical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Merdury Biopharmaceutical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Merdury Biopharmaceutical stock margins

The Merdury Biopharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merdury Biopharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merdury Biopharmaceutical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
84.30 %
- %
- %
Jan 1, 2020
84.30 %
- %
- %
Jan 1, 2021
84.30 %
- %
- %
Jan 1, 2022
43.73 %
-1,163.36 %
-1,166.04 %
Jan 1, 2023
57.31 %
-4,172.80 %
-4,241.63 %
Jan 1, 2024
84.30 %
-1,088.90 %
-1,018.90 %
Jan 1, 2025
84.30 %
- %
- %

Merdury Biopharmaceutical Stock Revenue, EBIT, Earnings per Share

The Merdury Biopharmaceutical earnings per share therefore indicates how much revenue Merdury Biopharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.00 TWD
-0.00 TWD
-0.00 TWD
Jan 1, 2020
0.00 TWD
0.00 TWD
0.00 TWD
Jan 1, 2021
0.00 TWD
0.00 TWD
0.00 TWD
Jan 1, 2022
0.01 TWD
-0.08 TWD
-0.08 TWD
Jan 1, 2023
0.00 TWD
-0.10 TWD
-0.11 TWD
Jan 1, 2024
0.01 TWD
-0.12 TWD
-0.11 TWD
Jan 1, 2025
0.00 TWD
-0.17 TWD
-0.16 TWD

Merdury Biopharmaceutical business model & stock analysis

Merdury Biopharmaceutical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Merdury Biopharmaceutical historical P/E ratio, EBIT multiple, and P/S ratio

Merdury Biopharmaceutical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Merdury Biopharmaceutical shares outstanding

The number of shares of Merdury Biopharmaceutical was 413.5 M in 2025. This indicates how many shares Merdury Biopharmaceutical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
406.48 M Stocks
Jan 1, 2020
406.48 M Stocks
Jan 1, 2021
406.48 M Stocks
Jan 1, 2022
401.50 M Stocks
Jan 1, 2023
416.06 M Stocks
Jan 1, 2024
457.55 M Stocks
Jan 1, 2025
413.50 M Stocks
Price targets and forecasts for Merdury Biopharmaceutical are not yet available.

Merdury Biopharmaceutical shareholder structure

% Name
0.00000%
State Street Investment Management (US)
State Street Investment Management (US)

Merdury Biopharmaceutical Beneficial Ownership Filings (SEC 13D/G)

Free Float
47.1%
Float Shares
-
Shares Outstanding
-

Merdury Biopharmaceutical Executives and Management Board

10 members · 25 % women

Management

PC

Mr. Phillip Chang

Chief Marketing Officer, Director · since 2022

–
CC

Ms. Chun-Chun Chang

Deputy General Manager-Administrative Division, Corporate Governance Officer

–
CC

Mr. Chaoyi Chen

Chief Research & Development Officer · since 2023

–

Board of Directors

YL

Mr. Yu-lung Lin

Chairman of the Board · since 2019

–
YL

Yaoren Liang

General Manager, Director · since 2019

–
JC

Mr. Jui-Hsin Chen

Director

–
FC

Fuxiang Chen

Independent Director

–
QC

Mr. Qunzhi Chen

Independent Director

–
PC

Mr. Ping-Ying Chiang

Independent Director

–

Frequently asked questions about Merdury Biopharmaceutical

Converted at the current exchange rate, the Merdury Biopharmaceutical share trades at 0.14 EUR (5.25 TWD).

No history available for Merdury Biopharmaceutical.

The revenue cannot currently be calculated for Merdury Biopharmaceutical.

The profit cannot currently be calculated for Merdury Biopharmaceutical.

The P/E ratio cannot be calculated for Merdury Biopharmaceutical at the moment.

The P/S cannot be calculated for Merdury Biopharmaceutical currently.

The Eulerpool Quality Score for Merdury Biopharmaceutical is 2/10.

The ISIN of Merdury Biopharmaceutical is TW0006932007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Merdury Biopharmaceutical is 6932.TWO. The ticker symbol is used to trade Merdury Biopharmaceutical shares on the stock exchange.

Merdury Biopharmaceutical paid dividends every year for the past 0 years.

Merdury Biopharmaceutical is assigned to the 'Health' sector.

The dividends of Merdury Biopharmaceutical are distributed in TWD.

All fundamentals and in-depth analysis of Merdury Biopharmaceutical

Our stock analysis for Merdury Biopharmaceutical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merdury Biopharmaceutical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Revenue→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Net Income→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical P/E→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical P/S→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical EBIT→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Dividend→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Directors Dealings→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Stocks→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Market capitalization→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Debt→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Liabilities→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Equity→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical AAQS→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Employees→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical ROE→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical ROA→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical ROCE→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical News→
Merdury Biopharmaceutical Stock
Merdury Biopharmaceutical Analyst Price Targets→

Health Stocks

Mereo BioPharma GroupMerck Tbk PTMeridian BioscienceMerck KGaAMerit Medical SystemsMerck & CoMesa LaboratoriesMerchavia Holdings and InvestmentsMesoblastMercator MedicalMetabiomed CoMera PharmaceuticalsAll Stocks A–Z →